Compare XERS & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XERS | GSBD |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2013 |
| Metric | XERS | GSBD |
|---|---|---|
| Price | $6.30 | $8.93 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $10.83 | $9.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | ★ 100.00 | 87.27 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $636.50 | ★ N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $8.66 |
| 52 Week High | $10.08 | $12.03 |
| Indicator | XERS | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 35.25 |
| Support Level | $6.26 | $8.89 |
| Resistance Level | $6.41 | $10.13 |
| Average True Range (ATR) | 0.28 | 0.23 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 28.50 | 8.77 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.